AbbVie Says EMA Validates MAA For Epcoritamab To Treat Relap

WASHINGTON (dpa-AFX) - AbbVie (ABBV) announced Friday that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for epcoritamab (DuoBody-CD3xCD20), an investigational

Related Keywords

Japan , Washington , United States , , European Medicines Agency , Drug Administration , Marketing Authorization Application , Biologics License Application , Abbvie , Ways , Validates , Epcoritamab , Treat , Relapsed , Refractory , Diffuse , Barge , Fell ,